CD19/CD3

N/A

Report date: 2026/03/19 16:52:45

Base Information

Drug NameCD19/CD3
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionB-lymphocyte antigen CD19 inhibitorsT cell surface glycoprotein CD3 inhibitors
TargetsB-lymphocyte antigen CD19T cell surface glycoprotein CD3
Therapy Area/IndicationsLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesWuhan Yzy Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWuhan Yzy Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A